Cohance Lifesciences · NSE: COHANCE · BSE: 543064
Q4 FY26 results · Jan–Mar 2026
Cohance Lifesciences reported revenue from operations of ₹619.12 crore (up 54.0% from Q4 FY25) and net profit of ₹8.31 crore (down 78.5% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 619.12 | 402.02 | +54.0% | 544.55 | +13.7% |
| Other income | (1.84) | 10.57 | Turned loss | 6.16 | Turned loss |
| Total income | 617.28 | 412.59 | +49.6% | 550.71 | +12.1% |
| Profit before tax | 19.91 | 51.60 | −61.4% | 40.60 | −51.0% |
| Net profit for the period | 8.31 | 38.73 | −78.5% | 29.02 | −71.4% |
| Attributable to shareholders of the company | 19.55 | 42.01 | −53.5% | 36.72 | −46.8% |
| EPS, basic (₹) | 0.51 | 1.65 | not comparable | 0.96 | −46.9% |
| Net margin (%) | 1.3 | 9.6 | 5.3 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 567.55 | 330.17 | +71.9% | 481.58 | +17.9% |
| Other income | (0.79) | 6.63 | Turned loss | 6.12 | Turned loss |
| Total income | 566.76 | 336.80 | +68.3% | 487.70 | +16.2% |
| Profit before tax | 56.44 | 56.32 | +0.2% | 65.43 | −13.7% |
| Net profit for the period | 34.56 | 44.34 | −22.1% | 47.29 | −26.9% |
| EPS, basic (₹) | 0.90 | 1.74 | not comparable | 1.24 | −27.4% |
| Net margin (%) | 6.1 | 13.4 | 9.8 |
Consolidated
- Filed with BSE
- 27 Jul 2026, 19:19 IST
- Board meeting
- 12 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 Jul 2026, 19:19 IST
- Board meeting
- 12 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE